Please assess the completion status of the following clinical trial:

Trial Title: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed HCC with serum AFP \>100ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP \>400ng/ml at time of screening and following most current line of therapy.~* Metastatic or locally advanced, unresectable HCC~* Must have failed or not tolerated at least two (2) different anti-HCC systemic agents~* Molecular Human Leukocyte Antigen (HLA) class I allele typing confirms participant carries at least one HLA-A2 allele~* Life expectancy of at least 4 months~* Karnofsky Performance Scale greater than or equal to 70~* At least 1 measurable lesion on imaging by RECIST~* Child-Pugh A6 or better~* Absolute neutrophil count greater than or equal to 1,500/mm\^3~* Platelet count greater than or equal to 75,000/mm\^3~Exclusion Criteria:~* Clinically significant cardiac disease~* Clinically significant pre-existing illness or active infection~* Clinically significant Central Nervous System (CNS) or neural dysfunction~* Active autoimmune disease requiring therapy~* Active malignancy other than HCC with the exception of cholangiocarcinoma (CCA) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement~* History of organ transplant~* Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction~* Advanced HCC involving greater than 50% of the liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ET140203 TCells (Type: EXPERIMENTAL): ET140203 T Cells

Based on this trial design, predict the completion outcome and termination type (if applicable).